Vanguard Capital Management
DNA icon

Vanguard Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Vanguard Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Buy
2,087,293
+172,865
+9% +$1.45M ﹤0.01% 2431
2026
Q1 		$11.7M Buy
+1,914,428
New +$15.9M ﹤0.01% 2641

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management's DNA Position: Q2 2026 in Review

Vanguard Capital Management increased its Ginkgo Bioworks (DNA) stake by 9% in Q2 2026, buying an estimated $1.45M and bringing the position to 2,087,293 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Vanguard Capital Management first reported a position in DNA in Q1 2026 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Vanguard Capital Management held 2,087,293 shares of Ginkgo Bioworks worth $20.7M as of Q2 2026.
  • Vanguard Capital Management bought 172,865 Ginkgo Bioworks shares in Q2 2026, an estimated $1.45M.
  • Ginkgo Bioworks made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2431 holding.
  • Vanguard Capital Management first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 2 quarters since.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.